Enterprise Value

687.9M

Cash

144.7M

Avg Qtr Burn

-61.17M

Short % of Float

17.88%

Insider Ownership

1.61%

Institutional Own.

92.78%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CIMERLI (CHS-201) (Lucentis biosimilar) Details
Eye disease , Wet age-related macular degeneration , Age-related macular degeneration

Approved

Quarterly sales

Approved

Quarterly sales

UDENYCA® (pegfilgrastim-cbqv) Biosimilar Details
Cancer, Chemotherapy-induced neutropenia

Approved

Quarterly sales

BLA

FDA meeting

Phase 3

Update

Toripalimab +/- CHS-006 (anti-TIGIT) (anti-PD-1) Details
Solid tumor/s, Non-small cell lung carcinoma, Hepatocellular carcinoma

Phase 1/2

Data readout

CHS-131 Details
Multiple sclerosis, Non-alcoholic steatohepatitis

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued